FDA Releases Guidance on Communication with the Agency
The agency publishes draft guidance on best practices for communication between FDA and IND sponsors during drug development.
FDA released draft guidance on Dec. 4, 2015 on the agency’s recommendations for best practices in communication between investigational new drug application (IND) sponsors and FDA during drug development. The guidance provides FDA’s expectations for methods of communication and timing of FDA responses to IND sponsor inquiries. It also details the types of advice and interactions that are appropriate between IND sponsors and FDA review teams.
The guidance does not apply to communications between FDA and industry trade organizations, consumer advocacy groups, other government agencies, or non-IND stakeholders. FDA states that the guidance will be updated as communication practices evolve.
Source: FDA
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
AES Clean Technology Launches Next-Generation OSM Utility Solution for Cleanrooms at INTERPHEX 2025
April 2nd 2025Officially launched at INTERPHEX 2025, the Omni ASCENT is a next-generation off-site manufactured vertical utility solution that offers optimized cleanroom flexibility and efficiency.
